Stichting Meander Medisch Centrum
- Address
- Maatweg 3, 3813 TZ Amersfoort, The Netherlands
Cardiovascular Diseases
The Cardiology department at Stichting Meander Medisch Centrum is advancing treatment options for patients with atrial fibrillation, focusing on safer anticoagulation to lower the risk of stroke and systemic embolism.
- Comparative effectiveness of novel oral anticoagulants
- Prevention of cardioembolic events
- Safety and tolerability profiling in real‑world settings
These studies aim to refine therapeutic choices and improve long‑term outcomes for individuals at high cardiovascular risk.
Neoplasms
Research in the oncology sphere targets non–small cell lung cancer with a specific focus on tumors that are KRAS p.G12C positive and lack PD‑L1 expression, evaluating the benefit of targeted agents such as sotorasib alongside chemotherapy.
- Targeted therapy for KRAS‑mutated lung cancer
- Combination strategies with immunotherapy
- Biomarker‑driven treatment selection
The goal is to enhance progression‑free survival and overall survival by personalizing treatment pathways for advanced disease patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Amgen Inc.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Stichting Meander Medisch Centrum
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Epcoritamab | 2 | Unknown | 2023-01-26 | 2023-01-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.